This is from the London presentation. Embryonic stem cell trials for macular degeneration. Structural evidence confirmed cells had attached and persisted. No signs of hyperproliferation, abnormal growth or rejection. Anatomical evidence of hESC-RPE survival and engraftment. Clinically increased pigmentation within the bed of the transplant. SMD patient: BCVA improved from hand motions to 20/800 and improved from 0 to 5 letters on the ETDRS visual acuity chart. Nine Month Follow-up: Visual acuity remain stable for both patients: SMD Patient continues to show improvement. Similar trends observed for latest AMD and SMD patients.
You can get the rest of the London presentation on ACTC website.
This is great news ACTC closed up at 0.089. The volume was not great only 6.3 million shares. Should have been 12 million at least with that news. We should up higher.
AAPL finally up big to close at $561.28 SHOULD go higher $590 this week.
Geron closed up a little at $1.40 on 895,325 shares, three month avg. volume 722,408 shares. No news.
Good luck in this rigged casino,
No comments:
Post a Comment